Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041691 · ClinicalTrials.gov registry record · Phase 1
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00041691 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 30 participants.
The verdict
NCT00041691, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of residual colorectal cancer following recent surgery.
Interventions
- DRUG hMN14 (labetuzumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041691
The ClinicalTrials.gov registry entry for NCT00041691 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hMN14 (labetuzumab) is the first listed.
NCT00041691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00041691 about?
NCT00041691 is a clinical study titled "Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery". The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of residual colorectal cancer following recent surgery.
What is the current status of trial NCT00041691?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants.
What interventions are being tested in trial NCT00041691?
The interventions under investigation include: hMN14 (labetuzumab) (DRUG).
Who is sponsoring clinical trial NCT00041691?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.